Every now and then the market completely loses interest in a sector. Right now that's health insurance and drug companies because the liberals are hammering on them in Congress.
This company is a scam anyways, but even money making companies like SUPN are getting slammed. Chart seems to indicate that it's got more room to drop.
I think MNK looks interesting at this price. Price has been driven down. Could potentially continue to fall, but in long run, this could be a good potential buy opportunity. Time will tell.
The IV% on short dated put options are much higher than normal. I sold a couple 3/2 $15P for .80/contract (3 days till expiration)
B.E. (or purchase price if exercised)...
We've been through DDD,VRX,GPRO to the recent TEVA stories to me MNK is just another.
Back to the days I was a proprietary trader, MNK is one of my favorite name as if I don't know what to trade in any given day I tried to short the name.
Only if we kept "it's never too low to sell" in mind that we can catch this kind of profit, otherwise we might be stopped out...
This price shows interesting features to go long: (1) a double bottom pattern, (2) a bullish resistance line breakout, (3) high volumen on a long tail candle which provides a reasonable stop loss (4) price just moved above the 50 day moving average.
Bough the possibly* weekly false brake(*will see at weekly close) on the support of the trading range.
Very similar to my previous MOS trade, will link to it for reference.
Hoping for a push higher and if closing above 80 area, a possible upgtrend follow-through, surpassing MOS trade results.
After the recent sell down below the US$44 level, buying interest emerged and price rallied towards US$54 level.
We may anticipate that the buying interest continues and may rally to US$58 and US$61.95.
With a strong buy recommendation from the consensus and a 55% target upside, this stock looks fundamentally compelling
The company has average revenue growth of 11% with an R.O.E. of 9.25% and an undemanding valuation (P.E. 12x, P/BV 1x)
The pharma sector might also provide interesting exposure, if the market decides to take a breather from...